Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jun 26;13(1):97.
doi: 10.1038/s41408-023-00867-x.

Monitoring measurable residual disease and chimerism in patients with JAK2 V617F-positive myelofibrosis after allogeneic hematopoietic cell transplantation

Jong-Mi Lee  1   2 , Ari Ahn  2   3 , Eun Jeong Min  4 , Sung-Eun Lee #  5   6 , Myungshin Kim #  7   8 , Yonggoo Kim  1   2
Affiliations

Monitoring measurable residual disease and chimerism in patients with JAK2 V617F-positive myelofibrosis after allogeneic hematopoietic cell transplantation

Jong-Mi Lee et al. Blood Cancer J. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1. Investigation of best-performing molecular markers for overt relapse.
A JAK2-MRD detection rate during 1 year of follow-up. B Comparison of JAK2-MRD VAF between relapsed and unrelapsed patients at different time points. C ROC curves of the JAK2-MRD VAF and JAK2-MRD ratio at D100. The JAK2-MRD VAF at D100 (dotted line) showed an AUC value of 0.877 and an optimal threshold of 0.021% with 100% sensitivity and 70% specificity (P < 0.001). The JAK2-MRD ratio at D100 (solid line) showed the best discriminative power for overt relapse (AUC: 0.983) at an optimal threshold of 2.877% with 100% sensitivity and 91.3% specificity (P < 0.001). D and E MC (donor chimerism <95%) rates by NGS and STR during 1 year of follow-up. F and G Comparison of donor chimerism measured by NGS and STR according to the over-relapse occurrences at different time points. Significant difference in the donor chimerism between the relapsed and unrelapsed patients was found in only NGS-chimerism at D180. H NGS-chimerism at D180 AUC value of 0.840 and optimal threshold of 76.63% with 60% sensitivity and 100% specificity (P = 0.001), but I STR-chimerism D180 showed no significant AUC values (P = 0.073). VAF variant allele frequency, ROC receiver operating characteristic, AUC area under the curve, MC mixed chimerism, CC complete chimerism, NGS next-generation sequencing, STR short tandem repeat.
Fig. 2
Fig. 2. Chronology of emerging relapse evidence and survival graphs.
A Swimmer plot of the 15 patients with relapse evidence and their outcomes, including 6 relapsed and 9 unrelapsed patients. The values of donor chimerism and JAK2-MRD VAF are presented in Supplementary Fig. 2. B Probability of overt relapse, relapse-free survival, and overall survival by JAK2-MRD ratio ≥3-fold at day +100. C Donor chimerism ≤77% at day +180, and D Donor chimerism ≤95% at day +180. Red positive, black negative. R-pt relapsed patient, UR-Pt unrelapsed patient, D day, MRD measurable residual disease, MC mixed chimerism, IST immunosuppressive therapy, VAF variant allele frequency, HCT hematopoietic stem cell transplantation, CI confidential interval, NA not available, MRD measurable residual disease, CIR cumulative incidence of relapse, RFS relapse-free survival, OS overall survival.
See this image and copyright information in PMC

References

    1. Tefferi A, Cervantes F, Mesa R, Passamonti F, Verstovsek S, Vannucchi AM, et al. Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. Blood. 2013;122:1395–8. doi: 10.1182/blood-2013-03-488098. - DOI - PMC - PubMed
    1. McLornan DP, Hernandez-Boluda JC, Czerw T, Cross N, Joachim Deeg H, Ditschkowski M, et al. Allogeneic haematopoietic cell transplantation for myelofibrosis: proposed definitions and management strategies for graft failure, poor graft function and relapse: best practice recommendations of the EBMT Chronic Malignancies Working Party. Leukemia. 2021;35:2445–59. doi: 10.1038/s41375-021-01294-2. - DOI - PubMed
    1. Kim DH, Seo J, Shin D-Y, Koh Y, Hong J, Kim I, et al. Reduced-intensity conditioning versus myeloablative conditioning allogeneic stem cell transplantation for patients with myelofibrosis. Blood Res. 2022;57:264–71. doi: 10.5045/br.2022.2022194. - DOI - PMC - PubMed
    1. Alchalby H, Badbaran A, Zabelina T, Kobbe G, Hahn J, Wolff D, et al. Impact of JAK2V617F mutation status, allele burden, and clearance after allogeneic stem cell transplantation for myelofibrosis. Blood. 2010;116:3572–81. doi: 10.1182/blood-2009-12-260588. - DOI - PubMed
    1. Wolschke C, Badbaran A, Zabelina T, Christopeit M, Ayuk F, Triviai I, et al. Impact of molecular residual disease post allografting in myelofibrosis patients. Bone Marrow Transplant. 2017;52:1526–9. doi: 10.1038/bmt.2017.157. - DOI - PubMed

Publication types